MA47736A - Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1 - Google Patents

Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1

Info

Publication number
MA47736A
MA47736A MA047736A MA47736A MA47736A MA 47736 A MA47736 A MA 47736A MA 047736 A MA047736 A MA 047736A MA 47736 A MA47736 A MA 47736A MA 47736 A MA47736 A MA 47736A
Authority
MA
Morocco
Prior art keywords
pyrimidopyrimidinones
wee
kinase
inhibitors
useful
Prior art date
Application number
MA047736A
Other languages
English (en)
Other versions
MA47736B1 (fr
Inventor
Frank Burkamp
Peter Hewitt
Hugues Miel
Colin O'dowd
Andrew Wilkinson
Original Assignee
Almac Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Discovery Ltd filed Critical Almac Discovery Ltd
Publication of MA47736A publication Critical patent/MA47736A/fr
Publication of MA47736B1 publication Critical patent/MA47736B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA47736A 2017-03-10 2018-03-12 Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1 MA47736B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1703881.1A GB201703881D0 (en) 2017-03-10 2017-03-10 Pharmaceutical compounds
PCT/GB2018/050620 WO2018162932A1 (fr) 2017-03-10 2018-03-12 Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1

Publications (2)

Publication Number Publication Date
MA47736A true MA47736A (fr) 2021-04-21
MA47736B1 MA47736B1 (fr) 2021-10-29

Family

ID=58605309

Family Applications (1)

Application Number Title Priority Date Filing Date
MA47736A MA47736B1 (fr) 2017-03-10 2018-03-12 Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1

Country Status (30)

Country Link
US (2) US11208413B2 (fr)
EP (1) EP3592745B1 (fr)
JP (1) JP7244430B2 (fr)
KR (1) KR102605546B1 (fr)
CN (1) CN110603256B (fr)
AU (1) AU2018231671B2 (fr)
BR (1) BR112019018753A2 (fr)
CA (1) CA3055874A1 (fr)
CL (1) CL2019002557A1 (fr)
CY (1) CY1124613T1 (fr)
DK (1) DK3592745T3 (fr)
EA (1) EA201992137A1 (fr)
ES (1) ES2895365T3 (fr)
GB (1) GB201703881D0 (fr)
HR (1) HRP20211652T1 (fr)
HU (1) HUE056220T2 (fr)
IL (1) IL269063B (fr)
LT (1) LT3592745T (fr)
MA (1) MA47736B1 (fr)
MX (1) MX2019010554A (fr)
MY (1) MY195580A (fr)
PH (1) PH12019502049A1 (fr)
PL (1) PL3592745T3 (fr)
PT (1) PT3592745T (fr)
RS (1) RS62464B1 (fr)
SA (1) SA519410093B1 (fr)
SG (1) SG11201908114UA (fr)
SI (1) SI3592745T1 (fr)
UA (1) UA125093C2 (fr)
WO (1) WO2018162932A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201703881D0 (en) * 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
WO2019074981A1 (fr) 2017-10-09 2019-04-18 GiraFpharma LLC Composés hétérocycliques et leurs utilisations
WO2019074979A1 (fr) 2017-10-09 2019-04-18 Girafpharma, Llc Composés hétérocycliques et leurs utilisations
US20220168313A1 (en) * 2019-04-09 2022-06-02 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
US20220162229A1 (en) * 2019-04-09 2022-05-26 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
KR20210150476A (ko) 2019-04-09 2021-12-10 누베이션 바이오 인크. 헤테로시클릭 화합물 및 그의 용도
EP4431511A1 (fr) * 2021-11-09 2024-09-18 Hangzhou Glubio Pharmaceutical Co. Ltd. Agent de dégradation de protéine kinase wee1 et son utilisation
AR128711A1 (es) * 2022-03-07 2024-06-05 Debiopharm Int Sa Métodos para tratar carcinoma microcítico de pulmón
WO2023217201A2 (fr) * 2022-05-10 2023-11-16 杭州德睿智药科技有限公司 Nouveau composé pyrimido-hétérocyclique servant d'inhibiteur de wee1 et son application

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196090B2 (en) 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
AR060635A1 (es) * 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
AU2009325400A1 (en) 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivatives
CN104271576A (zh) 2012-02-23 2015-01-07 艾伯维公司 激酶的吡啶并嘧啶酮抑制剂
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
GB201322602D0 (en) * 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
GB201703881D0 (en) * 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
AU2018231671B2 (en) 2022-03-24
EA201992137A1 (ru) 2020-02-05
AU2018231671A1 (en) 2019-09-26
ES2895365T3 (es) 2022-02-21
CA3055874A1 (fr) 2018-09-13
CN110603256B (zh) 2022-10-28
WO2018162932A1 (fr) 2018-09-13
IL269063B (en) 2022-04-01
US11208413B2 (en) 2021-12-28
DK3592745T3 (da) 2021-10-18
KR102605546B1 (ko) 2023-11-22
EP3592745B1 (fr) 2021-07-28
GB201703881D0 (en) 2017-04-26
CL2019002557A1 (es) 2019-12-27
PT3592745T (pt) 2021-10-20
PL3592745T3 (pl) 2022-01-03
HUE056220T2 (hu) 2022-02-28
RS62464B1 (sr) 2021-11-30
US20220194947A1 (en) 2022-06-23
JP2020510040A (ja) 2020-04-02
IL269063A (en) 2019-11-28
CN110603256A (zh) 2019-12-20
BR112019018753A2 (pt) 2020-04-07
KR20190128673A (ko) 2019-11-18
US20210128560A1 (en) 2021-05-06
SA519410093B1 (ar) 2022-07-16
CY1124613T1 (el) 2022-07-22
PH12019502049A1 (en) 2020-06-29
MY195580A (en) 2023-02-02
UA125093C2 (uk) 2022-01-05
HRP20211652T1 (hr) 2022-02-04
SG11201908114UA (en) 2019-10-30
MA47736B1 (fr) 2021-10-29
LT3592745T (lt) 2021-11-10
SI3592745T1 (sl) 2021-12-31
EP3592745A1 (fr) 2020-01-15
JP7244430B2 (ja) 2023-03-22
MX2019010554A (es) 2019-12-16

Similar Documents

Publication Publication Date Title
MA47736A (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1
MA54547A (fr) Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MA54546A (fr) Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
MA40587A (fr) Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA45646A (fr) Derives de benzimidazole comme des modulateurs de ror-gamma
MA42242A (fr) Inhibiteurs de la tyrosine kinase
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
MA46745A (fr) Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v
MA53110A (fr) Composés polycycliques en tant qu'inhibiteurs de la tyrosine-kinase de bruton
MA51232A (fr) Indane-amines utiles en tant qu'antagonistes de pd-l1
MA54567A (fr) Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma
DK3558278T3 (da) Flydende cannabinoidsammensætning
CL2018000520A1 (es) Proteinas inhibidoras de insectos novedosas
MA46878A (fr) Composés de benzodiazolium en tant qu'inhibiteurs d'enac
MA51337A (fr) Inhibiteurs spiro exo-aza de l'interaction ménine-mll
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase